Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced that its senior management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

The event will take place on June 10, 2024, at 2:40 p.m. Eastern Time in Miami, FL. The session will include a fireside chat, and a live webcast will be available on Repare's investor relations website.

The webcast replay will be accessible for 90 days post-event.

Positive

• Participation in a high-profile conference like the Goldman Sachs 45th Annual Global Healthcare Conference can enhance visibility and credibility.
• The live webcast and its 90-day replay availability improve investor access to information.

Negative

• The press release lacks specific financial or clinical updates that could give investors concrete insights into the company's performance.
• No immediate business impact or new developments are announced, which might leave investors wanting more substantial news.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern Time in Miami, FL.

A live webcast of the fireside can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603375233/en/

Investor Relations & Media:



Robin Garner

Vice President and Head of Investor Relations

Repare Therapeutics Inc.

investor@reparerx.com

Source: Repare Therapeutics Inc.

FAQ

When is Repare Therapeutics participating in the Goldman Sachs 45th Annual Global Healthcare Conference?

Repare Therapeutics will participate on June 10, 2024, at 2:40 p.m. Eastern Time.

Where can I watch the Repare Therapeutics fireside chat at the Goldman Sachs Healthcare Conference?

A live webcast will be available on the investor section of Repare's website.

How long will the webcast replay of Repare Therapeutics' session be available?

The webcast replay will be archived on the company's website for 90 days.